Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Neil Herskowitz is Director at Journey Medical. OQRO lists 3 transactions filed with the SEC under this name, the latest on Jul 2, 2026, each linked to the official Form 4.
Director
Disclosures on record
3
Companies involved
2
Journey MedicalDERM
2 disclosures · Jun 2026 – Jul 2026
Jul 1, 202650Kdisclosed Jul 2
DetailsOfficial recordJun 25, 202610Kdisclosed Jun 26
DetailsOfficial recordMustang BioMBIO
Dec 30, 2025Sold~$238
DetailsOfficial recordAs of the latest filing on , Neil Herskowitz reported holding 168,618 shares of Journey Medical (DERM), worth about $624K at the last close of $4 (Nov 16, 2026). Holdings are also on file at Mustang Bio (MBIO); together they are worth about $624K. In the last 12 months, Neil Herskowitz sold $238 in 1 sale.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Journey Medical DERM | 168,618 | 169K direct | $4 | $624K | Jul 1, 2026 |
| Mustang Bio MBIO | 145 | 145 direct | $0 | $57 | Dec 30, 2025 |
Is this Neil Herskowitz’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Neil Herskowitz bought shares on the open market in 2006, 2007, 2012 and 2018, and has not bought since 2018 across 2 companies. Sales in 1 of the 21 years since 2006.
Neil Herskowitz reported 8 open-market purchases and 1 sale since 2006; purchases in 4 different years, most recently 2018.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $2381×1 trade |
| 2018 | $4K1×1 trade | — |
| 2012 | $2K1×1 trade | — |
| 2007 | $50K1×1 trade | — |
| 2006 | $25K5×5 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Jul 1, 2026, Neil Herskowitz reported holding 168,618 shares of Journey Medical (DERM). At the last close of $4 on Nov 16, 2026, that is about $624K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Neil Herskowitz reported 1 open-market sale worth $238, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Neil Herskowitz bought shares on the open market in 2006, 2007, 2012 and 2018, and has not bought since 2018 across 2 companies. Sales in 1 of the 21 years since 2006.
In SEC filings since 2006: the latest open-market purchase is from 2018; the latest open-market sale is from 2025.
2 companies: Mustang Bio (MBIO, 2018–2025), TG Therapeutics, Inc. (TGTX, 2006–2012).
Neil Herskowitz reported 7 open-market purchases and 0 sales here, 2006 to 2012.
Neil Herskowitz reported 1 open-market purchase and 1 sale here, 2018 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.